Arbutus Biopharma Corp
ABUS · Biotech · Nasdaq · As of 10 Sep 2026
- FundamentalsNot enough data yet
- ValueNot enough data yet
- News flowBalanced
- MomentumStrong
- SafetyBalanced
Overall confidence 38/100 — few inputs available yet
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.
Discovery Gap: High (44/100) · Gap confidence 53/100Filings show more traction than the tape reflects.
This month at a glance
AIR Score™ change: 0AIR Score™ held steady this month.
Cycle window9 Sep 2026 → 10 Sep 2026
MoversNothing moved meaningfully this month.
Evidence timeline
- [8-K 8.01] Arbutus Biopharma Corp — Other EventsSEC · SEC EDGARAug 21, 2026 · FORM 8-K
- [8-K 2.02] Arbutus Biopharma Corp — Results of Operations and Financial ConditionSEC · SEC EDGARAug 12, 2026 · FORM 8-K
- [8-K 5.02] Arbutus Biopharma Corp — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARJul 15, 2026 · FORM 8-K
- [8-K 1.02] Arbutus Biopharma Corp — Termination of a Material Definitive AgreementSEC · SEC EDGARJul 15, 2026 · FORM 8-K
- [8-K 8.01] Arbutus Biopharma Corp — Other EventsSEC · SEC EDGARJul 15, 2026 · FORM 8-K
- [8-K 5.02] Arbutus Biopharma Corp — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARMay 26, 2026 · 8-K
- [8-K 2.02] Arbutus Biopharma Corp — Results of Operations and Financial ConditionSEC · SEC EDGARMay 13, 2026 · FORM 8-K
- [8-K 8.01] Arbutus Biopharma Corp — Other EventsSEC · SEC EDGARApr 14, 2026 · FORM 8-K
- [8-K 2.02] Arbutus Biopharma Corp — Results of Operations and Financial ConditionSEC · SEC EDGARMar 23, 2026 · FORM 8-K
- [8-K 1.01] Arbutus Biopharma Corp — Entry into a Material Definitive AgreementSEC · SEC EDGARMar 3, 2026 · FORM 8-K
- [8-K 8.01] Arbutus Biopharma Corp — Other EventsSEC · SEC EDGARMar 3, 2026 · FORM 8-K
- [8-K 8.01] Arbutus Biopharma Corp — Other EventsSEC · SEC EDGARFeb 17, 2026 · FORM 8-K
Ask AIR
What would change our view
A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.